Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

BACKGROUND: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has been associated with response to anthracyclines. Limited information exists on...

Descripción completa

Detalles Bibliográficos
Autores principales: Fountzilas, George, Dafni, Urania, Bobos, Mattheos, Kotoula, Vassiliki, Batistatou, Anna, Xanthakis, Ioannis, Papadimitriou, Christos, Kostopoulos, Ioannis, Koletsa, Triantafillia, Tsolaki, Eleftheria, Televantou, Despina, Timotheadou, Eleni, Koutras, Angelos, Klouvas, George, Samantas, Epaminontas, Pisanidis, Nikolaos, Karanikiotis, Charisios, Sfakianaki, Ioanna, Pavlidis, Nicholas, Gogas, Helen, Linardou, Helena, Kalogeras, Konstantine T, Pectasides, Dimitrios, Dimopoulos, Meletios A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621498/
https://www.ncbi.nlm.nih.gov/pubmed/23537287
http://dx.doi.org/10.1186/1471-2407-13-163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621498/
https://www.ncbi.nlm.nih.gov/pubmed/23537287
http://dx.doi.org/10.1186/1471-2407-13-163

Ejemplares similares